Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849952 · ClinicalTrials.gov registry record
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- 94
- Enrollment target
NCT01849952: Clinical Trial study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT01849952 is a clinical trial that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01849952 was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- 94 participants
- Enrollment target
Study Summary
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.
Primary Outcome
Patients will be followed for survival every 12 weeks +/- 1 week.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2013-10-09 |
| Est. Completion | 2025-08-25 |
Why NCT01849952 stopped before completion
NCT01849952 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 94 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01849952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01849952 about?
NCT01849952 is a clinical study titled "Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas". MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed a...
What is the current status of trial NCT01849952?
This trial is currently terminated. The enrollment target is 94 participants. The study started on 2013-10-09. Estimated completion is 2025-08-25.
Who is sponsoring clinical trial NCT01849952?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI